1. A score that predicts one year functional status in anti-NMDA receptor encephalitis patients. 2. [What's Trending]: Part 2: Drug pricing and the Institute for Clinical and Economic Review framework. In the first segment, Dr. David Lapides talks with Dr. Ramani Balu about his paper on a score that predicts one year functional status in anti-NMDA receptor encephalitis patients. In the second part of the podcast, you'll hear the the second part of Dr. Gordon Smith's interview with Dr. Steve Pearson on the Institute for Clinical and Economic Review and drug pricing. DISCLOSURES: Dr. David Lapides has served as a consultant for Board Vitals; and has received foundation/society research support from the National Multiple Sclerosis Society Clinical Fellowship. Dr. Ramani Balu has received governmental research support from the National Institutes of Health and the Department of Defense. Dr. A. Gordon Smith has served on the scientific advisory board of the Regenesis Data Monitoring Committee; has served on the editorial boards for Continuum and Annals of Clinical and Translational Neurology; has served as a consultant for Regenesis; has served on the speakers' bureau for Alexion; has received commercial research support from Impeto Medical SAS; and has received governmental research support from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Neurological Disorders and Stroke. Dr. Steve Pearson's Institute for Clinical and Economic Review has received membership dues from Aetna, Alnylam, America’s Health Insurance Plans (AHIP), Anthem, AstraZeneca, Blue Shield of CA, Cambia Health Solution, CVS, Caremark, Editas, Express Scripts, Genentech, GlaxoSmithKline, Harvard Pilgrim Health Care, Health Care Service Corporation (HCSC), HealthPartners, Johnson & Johnson, Kaiser Permanente, Mallinckrodt Pharmaceuticals, Merck & Co., National Pharmaceutical Council (NPC), Novartis, Premera Blue Cross, Prime Therapeutics, Regeneron, Sanofi, and United Healthcare; and has received foundation/society research support from the Laura and John Arnold Foundation, the California Health Care Foundation, Blue Shield of California Foundation, Kaiser, East Bay Community Foundation, and the Commonwealth Fund.